129 related articles for article (PubMed ID: 28500289)
1. Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.
Yoshimaru T; Aihara K; Komatsu M; Matsushita Y; Okazaki Y; Toyokuni S; Honda J; Sasa M; Miyoshi Y; Otaka A; Katagiri T
Sci Rep; 2017 May; 7(1):1821. PubMed ID: 28500289
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
Yoshimaru T; Komatsu M; Miyoshi Y; Honda J; Sasa M; Katagiri T
Cancer Sci; 2015 May; 106(5):550-8. PubMed ID: 25736224
[TBL] [Abstract][Full Text] [Related]
3. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.
Yoshimaru T; Komatsu M; Matsuo T; Chen YA; Murakami Y; Mizuguchi K; Mizohata E; Inoue T; Akiyama M; Yamaguchi R; Imoto S; Miyano S; Miyoshi Y; Sasa M; Nakamura Y; Katagiri T
Nat Commun; 2013; 4():2443. PubMed ID: 24051437
[TBL] [Abstract][Full Text] [Related]
4. Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.
Yoshimaru T; Komatsu M; Tashiro E; Imoto M; Osada H; Miyoshi Y; Honda J; Sasa M; Katagiri T
Sci Rep; 2014 Dec; 4():7355. PubMed ID: 25483453
[TBL] [Abstract][Full Text] [Related]
5. BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.
Kim NH; Yoshimaru T; Chen YA; Matsuo T; Komatsu M; Miyoshi Y; Tanaka E; Sasa M; Mizuguchi K; Katagiri T
PLoS One; 2015; 10(6):e0127707. PubMed ID: 26052702
[TBL] [Abstract][Full Text] [Related]
6. A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells.
Yoshimaru T; Ono M; Bando Y; Chen YA; Mizuguchi K; Shima H; Komatsu M; Imoto I; Izumi K; Honda J; Miyoshi Y; Sasa M; Katagiri T
Nat Commun; 2017 May; 8():15427. PubMed ID: 28555617
[TBL] [Abstract][Full Text] [Related]
7. The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.
Toki S; Yoshimaru T; Matsushita Y; Aihara H; Ono M; Tsuneyama K; Sairyo K; Katagiri T
Cancer Sci; 2021 Oct; 112(10):4208-4219. PubMed ID: 34363714
[TBL] [Abstract][Full Text] [Related]
8. Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.
Kim JW; Akiyama M; Park JH; Lin ML; Shimo A; Ueki T; Daigo Y; Tsunoda T; Nishidate T; Nakamura Y; Katagiri T
Cancer Sci; 2009 Aug; 100(8):1468-78. PubMed ID: 19496786
[TBL] [Abstract][Full Text] [Related]
9. Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction.
Chigira T; Nagatoishi S; Takeda H; Yoshimaru T; Katagiri T; Tsumoto K
Biochem Biophys Res Commun; 2019 Oct; 518(1):183-189. PubMed ID: 31421830
[TBL] [Abstract][Full Text] [Related]
10. Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type α-helical structure.
Chen YA; Murakami Y; Ahmad S; Yoshimaru T; Katagiri T; Mizuguchi K
BMC Res Notes; 2014 Jul; 7():435. PubMed ID: 24997568
[TBL] [Abstract][Full Text] [Related]
11. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
12. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
13. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
14. Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.
Chigira T; Nagatoishi S; Tsumoto K
Biochem Biophys Res Commun; 2015 Aug; 463(4):726-31. PubMed ID: 26049107
[TBL] [Abstract][Full Text] [Related]
15. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
17. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
19. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
20. Activation of ClC-3 chloride channel by 17β-estradiol relies on the estrogen receptor α expression in breast cancer.
Yang H; Ma L; Wang Y; Zuo W; Li B; Yang Y; Chen Y; Chen L; Wang L; Zhu L
J Cell Physiol; 2018 Feb; 233(2):1071-1081. PubMed ID: 28419445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
